New directions in the treatment of hyperprolactinemia

Endocrinologist

Volumn 7, Issue 3, 1997, Pages 153-159

  Vance, Mary Lee ^a  

^a UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; PERGOLIDE MESILATE; PROGESTERONE; PROLACTIN; QUINAGOLIDE; SEX HORMONE; TESTOSTERONE;

CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; GASTROINTESTINAL TOXICITY; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; MICROADENOMA; ORTHOSTATIC HYPOTENSION; PREGNANCY; PROLACTINOMA; REVIEW; TREATMENT INDICATION;

EID: 0030939730     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-199707030-00004     Document Type: Review

References (36)

1. Boulanger CM, Mashchak CA, Chang RJ: Lack of tumor reduction in hyperprolactinemic women with extrasellar macroadenomas treated with bromocriptine. Fertil Steril 1985; 44: 532-5.
2. Post KD, Biller BJ, Adelman LS, et al.: Selective transsphenoidal adenomectomy in woman with galactorrhea-amenorrhea. JAMA 1979; 242: 158-62.
3. Hardy J: Transsphenoidal microsurgery of prolactinomas. In Secretory Tumors of the Pituitary Gland (Progress in Endocrine Research and Therapy, Vol 1), edited by Black PM, Zervas NT, Ridgway EC, et al., pp. 73-81, Newark, NJ, Raven Press 1984.
4. Frantz AG, Cogon PH, Chang CH, et al.: Long-term evaluation of the results of transsphenoidal surgery and radiotherapy in patients with prolactinoma. In Endocrinology of Human Infertility: New Aspects, edited by Crosignani PG, Rubin BL, pp. 161-70, New York, Grune and Stratton 1981.
5. Nelson PB, Goodman ML, Flickenger JC, et al.: Endocrine function in patients with large pituitary tumors treated with operative decompression and radiation therapy. Neurosurgery 1989; 24: 398-400.
6. Hashimoto N, Handa H, Yamashita J, et al.: Long-term follow-up of large or invasive pituitary adenomas. Surg Neurol 1986; 25: 49-54.
7. Laws ER.: Surgical management of pituitary tumors. In Endocrine Times, edited by Mazzaferri EL, Samaan N, pp. 215-20, Boston, Blackwell 1993.
8. Snyder PJ, Fowble BF, Schatz NJ, et al.: Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986; 81: 457-62.
9. Constine LS, Woolf PD, Cann D, et al.: Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328: 87-94.
10. Thorner MO, Schran HF, Evans WS, et al.: A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J Clin Endocrinol Metab 1980; 50: 1026-33.
11. Molitch ME, Elton RL, Blackwell RE, et al.: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985; 60: 698-705.
12. Thorner MO, Martin WH, Rogol AD, et al.: Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab 1980; 51: 438-45.
13. Vermesh M, Fossum GT, Kletzky OA: Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. Obstet Gynecol 1988; 72: 693-8.
14. Kletzky OA, Vermesh M: Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertil Steril 1989; 51: 269-72.
15. Kendall-Taylor P, Hall K, Johnston DG, et al.: Reduction in size of prolactin-secreting tumors in men treated with pergolide. Br Med J 1982; 285: 465-7.
16. Kleinberg DL, Boyd AE, Wardlaw S, et al.: Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983; 309: 704-9.
17. Franks S, Horrocks PM, Lynch SS, et al.: Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia. Br Med J 1983; 286: 1177-9.
18. Vance ML, Cragun JR, Reimnitz C, et al.: CV 205-502 treatment of hyperprolactinemia. J Clin Endocrinol Metab 1989; 68: 336-9.
19. Vance ML, Lipper M, Klibanski A, et al.: Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann Intern Med 1990; 112: 668-72.
20. Newman CB, Hurley AM, Kleinberg DL: Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine. Clin Endocrinol 1989; 31: 392-400.
21. Chang RJ, Keye WR Jr, Young JR, et al.: Detection, evaluation, and treatment of pituitary microadenomas in patients with galactorrhea and amenorrhea. Am J Obstet Gynecol 1977; 128: 356-63.
22. Webster J, Piscitelli G, Polli A, et al.: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904-9.
23. Webster J, Piscitelli G, Polli A, et al.: Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. Clin Endocrinol 1992; 37: 534-41.
24. Biller BMK, Molitch ME, Vance ML, et al.: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81: 2338-43.
25. Pellegrini I, Rasolonjanahary R, Gunz G, et al.: Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989; 69: 500-9.
26. Turkalj I, Braun P, Krupp P: Surveillance of bromocriptine in pregnancy. JAMA 1982; 247: 1589-91.
27. Robert E, Musatti L, Piscitelli G, et al.: Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996; 10: 333-7.
28. Molitch ME: Medical intelligence current concepts: pregnancy and the hyperprolactinemic woman. N Engl J Med 1985; 312: 1364-70.
29. Van Roon E, Van Der Vijver, JCM, Gerretsen G, et al.: Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy. Fertil Steril 1981; 36: 173-7.
30. Konopka P, Raymond JP, Merceron RE, et al.: Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 1983; 146: 935-8.
31. Lamberts SWJ, Klijn JGM, DeLange SA, et al.: The incidence of complications during pregnancy after treatment of hyperprolactinemia with bromocriptine in patients with radiological evidence pituitary tumors. Fertil Steril 1979; 31: 614-19.
32. Klibanski A, Neer RM, Beitins IZ, et al.: Medical intelligence: decreased bone density in hyperprolactinemic women. N Engl J Med 1980; 303: 1511-14.
33. Greenspan SL, Oppenheim DS, Klibanski A: Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989; 110: 526-31.
34. Greenspan SL, Neer RM, Ridgway EC, et al.: Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 1986; 104: 777-82.
35. Davis JRE, Selby C, Jeffcoate WJ: Oral contraceptive agents do not affect serum prolactin in normal women. Clin Endocrinol 1984; 20: 427-34.
36. Moult PJA, Dacie JE, Rees LH, et al.: Oral contraception in patients with hyperprolactinaemia. Br Med J 1982; 284.